DK2027156T3 - Hepatocytvækstfaktor (HGF)bindingsprotein - Google Patents

Hepatocytvækstfaktor (HGF)bindingsprotein

Info

Publication number
DK2027156T3
DK2027156T3 DK07795599.5T DK07795599T DK2027156T3 DK 2027156 T3 DK2027156 T3 DK 2027156T3 DK 07795599 T DK07795599 T DK 07795599T DK 2027156 T3 DK2027156 T3 DK 2027156T3
Authority
DK
Denmark
Prior art keywords
hgf
growth factor
binding protein
hepatocyte growth
hepatocyte
Prior art date
Application number
DK07795599.5T
Other languages
English (en)
Inventor
S Kirk Wright
William M Winston
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2027156T3 publication Critical patent/DK2027156T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK07795599.5T 2006-06-02 2007-06-01 Hepatocytvækstfaktor (HGF)bindingsprotein DK2027156T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
DK2027156T3 true DK2027156T3 (da) 2011-04-26

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07795599.5T DK2027156T3 (da) 2006-06-02 2007-06-01 Hepatocytvækstfaktor (HGF)bindingsprotein

Country Status (21)

Country Link
US (5) US7649083B2 (da)
EP (2) EP2027156B9 (da)
JP (3) JP4686634B2 (da)
KR (1) KR101196060B1 (da)
AR (1) AR061171A1 (da)
AT (1) ATE495195T1 (da)
AU (1) AU2007254942B2 (da)
BR (1) BRPI0712222B1 (da)
CA (1) CA2654025C (da)
CY (1) CY1111714T1 (da)
DE (1) DE602007011923D1 (da)
DK (1) DK2027156T3 (da)
HK (1) HK1129395A1 (da)
IL (2) IL195037A (da)
MX (1) MX2008014829A (da)
NO (1) NO345476B1 (da)
NZ (1) NZ573818A (da)
PL (1) PL2027156T3 (da)
PT (1) PT2027156E (da)
SG (1) SG158112A1 (da)
WO (1) WO2007143090A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53476B (en) 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
WO2007143090A2 (en) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
EP2380908A1 (en) * 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
HUE027154T2 (en) 2007-07-02 2016-08-29 Oncomed Pharm Inc Preparations and procedures for the treatment and diagnosis of cancer
EA201000903A1 (ru) 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa
NZ588029A (en) * 2008-03-14 2012-12-21 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
WO2009148928A1 (en) 2008-05-29 2009-12-10 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
KR20140048276A (ko) 2011-07-15 2014-04-23 온코메드 파마슈티칼스, 인크. Rspo 결합제 및 이의 용도
MX2014002762A (es) 2011-09-09 2014-07-30 Amgen Inc Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico.
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
KR20150036603A (ko) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 결합제 및 그의 용도
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
EP4013869A1 (en) 2019-08-12 2022-06-22 InteRNA Technologies B.V. New treatments involving mirna-193a
CA3167367A1 (en) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Mirna-193a for promoting immunogenic cell death
CN116234814A (zh) * 2020-08-28 2023-06-06 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU1598801A (en) 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
RS53476B (en) 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
EP1885400A4 (en) 2005-06-02 2011-01-26 Galaxy Biotech Llc METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007143090A2 (en) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
EP2380908A1 (en) 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
IL219654A0 (en) 2012-06-28
NO20085421L (no) 2009-02-27
IL195037A0 (en) 2011-08-01
DE602007011923D1 (de) 2011-02-24
SG158112A1 (en) 2010-01-29
US7943344B2 (en) 2011-05-17
AU2007254942A8 (en) 2009-02-05
JP5735476B2 (ja) 2015-06-17
NO345476B1 (no) 2021-02-22
ATE495195T1 (de) 2011-01-15
US20080108565A1 (en) 2008-05-08
US7649083B2 (en) 2010-01-19
AU2007254942A1 (en) 2007-12-13
EP2361934A3 (en) 2011-11-02
US9096664B2 (en) 2015-08-04
WO2007143090A3 (en) 2008-03-13
US20110229462A1 (en) 2011-09-22
JP2009539347A (ja) 2009-11-19
CA2654025C (en) 2016-08-02
EP2361934A2 (en) 2011-08-31
WO2007143090A2 (en) 2007-12-13
KR101196060B1 (ko) 2012-11-01
US20100173362A1 (en) 2010-07-08
US20130203963A1 (en) 2013-08-08
JP2011072318A (ja) 2011-04-14
BRPI0712222B1 (pt) 2021-10-13
EP2027156B1 (en) 2011-01-12
EP2027156A2 (en) 2009-02-25
CY1111714T1 (el) 2015-10-07
MX2008014829A (es) 2009-01-29
JP2013090632A (ja) 2013-05-16
US8273355B2 (en) 2012-09-25
EP2027156B9 (en) 2011-03-30
HK1129395A1 (en) 2009-11-27
NZ573818A (en) 2011-09-30
KR20090027226A (ko) 2009-03-16
IL195037A (en) 2015-08-31
CA2654025A1 (en) 2007-12-13
JP4686634B2 (ja) 2011-05-25
PL2027156T3 (pl) 2011-06-30
US20140178935A1 (en) 2014-06-26
PT2027156E (pt) 2011-04-18
US8580930B2 (en) 2013-11-12
BRPI0712222A2 (pt) 2012-01-10
AU2007254942B2 (en) 2011-10-27
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
DK2027156T3 (da) Hepatocytvækstfaktor (HGF)bindingsprotein
HK1129394A1 (en) Hepatocyte growth factor (hgf) binding proteins
CY2020009I1 (el) Δεσμευτικοι παραγοντες σκληροστινης
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
CY2016029I1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
DK2046826T3 (da) Exendin-fusionsproteiner
BRPI0716438A2 (pt) Proteínas ligantes interleucina-1,3
DK1776383T3 (da) Bindingsmolekyler
DK3118220T3 (da) Protein
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
DE502005003444D1 (de) Drohne
DE602006011613D1 (de) Absaugsteuerung
BRPI0814971A2 (pt) Proteína
DK1809660T3 (da) Thymus-specifikt protein
ITGE20050091A1 (it) Incubatrice
DE502005000305D1 (de) Photobioreaktor
GB0610140D0 (en) Protein stability
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
DE602004029820D1 (de) Stütze mit versteifungsmitteln
FI20050547A0 (fi) Side
AT504183A3 (de) Skibindungssystem
DK2219663T3 (da) Revers-protein
ITCN20060002A1 (it) Imbiellaggio martino